Quetiapine fumarate for the treatment of multiple sclerosis: Focus on myelin repair

CNS Neuroscience and Therapeutics

Volumn 19, Issue 10, 2013, Pages 737-744

  Zhornitsky, Simon ^a,b   Wee Yong, Voon ^a,b   Koch, Marcus W ^a,b   Mackie, Aaron ^a   Potvin, Stéphane ^c   Patten, Scott B ^a,b   Metz, Luanne M ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE MONTRÉAL   (Canada)

Author keywords

Multiple sclerosis; Neuroprotection; Oligodendrocyte; Quetiapine fumarate; Remyelination

Indexed keywords

AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CUPRIZONE; DIZOCILPINE; DULOXETINE; FLUOXETINE; FREE RADICAL; HALOPERIDOL; MYELIN; NEUROTROPHIC FACTOR; OLANZAPINE; QUETIAPINE; TIAPRIDE;

AKATHISIA; ALLERGIC ENCEPHALOMYELITIS; ANXIETY; ASTROCYTE; BACKACHE; BRAIN ISCHEMIA; CELL MATURATION; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DEMYELINATION; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; FATIGUE; HUMAN; IMMUNOMODULATION; INSOMNIA; MICROGLIA; MULTIPLE SCLEROSIS; NAUSEA; NERVE CELL; NERVE FIBER DEGENERATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PARKINSONISM; REVIEW; SEDATION; SIDE EFFECT; T LYMPHOCYTE; WELLBEING; XEROSTOMIA;

MULTIPLE SCLEROSIS; NEUROPROTECTION; OLIGODENDROCYTE; QUETIAPINE FUMARATE; REMYELINATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; TREATMENT OUTCOME;

EID: 84884813051     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12154     Document Type: Review

References (88)

1. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;122:1180-1188.
2. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012;13:507-514.
3. Zhornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. Mult Scler 2013;19:15-23.
4. Franklin RJ, ffrench-Constant C, Edgar JM, et al. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012;8:624-634.
5. Tselis A, Khan OA, Lisak RP. Approaches to neuroprotective strategies in multiple sclerosis. Expert Opin Pharmacother 2010;11:2869-2878.
6. De Keyser J, Laureys G, Demol F, Wilczak N, Mostert J, Clinckers R. Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem Int 2010;57:446-450.
7. Siffrin V, Radbruch H, Glumm R, et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010;33:424-436.
8. Domercq M, Vázquez-Villoldo N, Matute C. Neurotransmitter signaling in the pathophysiology of microglia. Front Cell Neurosci 2013;7:49.
9. Loers G, Aboul-Enein F, Bartsch U, Lassmann H, Schachner M. Comparison of myelin, axon, lipid, and immunopathology in the central nervous system of differentially myelin-compromised mutant mice: A morphological and biochemical study. Mol Cell Neurosci 2004;27:175-189.
10. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-2312.
11. Xiao L, Xu H, Zhang Y, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008;13:697-708.
12. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-359.
13. Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompré PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: A systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol 2011;26:183-192.
14. Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:71-77.
15. Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand S. Add-on treatment of quetiapine for fibromyalgia: A pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol 2012;32:684-687.
16. Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: A double blind, randomized controlled trial. J Med Assoc Thai 2010;93:729-734.
17. Krymchantowski AV, Jevoux C, Moreira PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med 2010;11:48-52.
18. Zhang Y, Xu H, Jiang W, et al. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr Res 2008;106:182-191.
19. Xu H, Yang HJ, McConomy B, Browning R, Li XM. Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: Effects of antipsychotics. Front Behav Neurosci 2010;4:8.
20. Chandran P, Upadhyay J, Markosyan S, et al. Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 2012;202:446-453.
21. Xu H, Yang HJ, Li XM. Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizone. Eur Arch Psychiatry Clin Neurosci 2013 [Epub ahead of print].
22. Zhang Y, Zhang H, Wang L, et al. Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res 2012;138:8-17.
23. Bi X, Zhang Y, Yan B, et al. Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice. J Neurochem 2012;123:14-20.
24. Mei F, Guo S, He Y, et al. Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation. PLoS ONE 2012;7:e42746.
25. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: New insights into an old story. Acta Neuropathol 2009;118:723-736.
26. McTigue DM, Tripathi RB. The life, death, and replacement of oligodendrocytes in the adult CNS. J Neurochem 2008;107:1-19.
27. Yan B, Bi X, He J, et al. Quetiapine attenuates spatial memory impairment and hippocampal neurodegeneration induced by bilateral common carotid artery occlusion in mice. Life Sci 2007;81:353-361.
28. Yan B, He J, Xu H, et al. Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice. Behav Brain Res 2007;182:36-41.
29. Ransohoff RM. Animal models of multiple sclerosis: The good, the bad and the bottom line. Nat Neurosci 2012;15:1074-1077.
30. Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: Therapeutic modulation via fumaric acid esters. Int J Mol Sci 2012;13:11783-11803.
31. Dasgupta A, Zheng J, Perrone-Bizzozero NI, Bizzozero OA. Increased carbonylation, protein aggregation and apoptosis in the spinal cord of mice with experimental autoimmune encephalomyelitis. ASN Neuro 2013;5:e00111.
32. Qing H, Xu H, Wei Z, Gibson K, Li XM. The ability of atypical antipsychotic drugs vs. haloperidol to protect PC12 cells against MPP+-induced apoptosis. Eur J Neurosci 2003;17:1563-1570.
33. Bai O, Wei Z, Lu W, Bowen R, Keegan D, Li XM. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J Neurosci Res 2002;69:278-283.
34. Tan QR, Wang XZ, Wang CY, et al. Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells. Eur Neuropsychopharmacol 2007;17:768-773.
35. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 2005;81:572-580.
36. Xu H, Wang H, Zhuang L, et al. Demonstration of an anti-oxidative stress mechanism of quetiapine: Implications for the treatment of Alzheimer's disease. FEBS J 2008;275:3718-3728.
37. Miljević Č, Nikolić-Kokić A, Nikolić M, et al. Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study). Hum Psychopharmacol 2013;28:1-6.
38. Dietrich-Muszalska A, Kontek B, Rabe-Jabłońska J. Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro. Neuropsychobiology 2011;63:197-201.
39. Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010;479:317-320.
40. Lühder F, Gold R, Flügel A, Linker RA. Brain-derived neurotrophic factor in neuroimmunology: Lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Arch Immunol Ther Exp (Warsz) 2013;61:95-105.
41. VonDran MW, Singh H, Honeywell JZ, Dreyfus CF. Levels of BDNF impact oligodendrocyte lineage cells following a cuprizone lesion. J Neurosci 2011;31:14182-14190.
42. Linker RA, Lee DH, Demir S, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: Therapeutic implications in a model of multiple sclerosis. Brain 2010;133:2248-2263.
43. Lee DH, Geyer E, Flach AC, et al. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol 2012;123:247-258.
44. Skihar V, Silva C, Chojnacki A, et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U S A 2009;106:17992-17997.
45. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002;321:65-68.
46. Park SW, Lee SK, Kim JM, et al. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett 2006;402:25-29.
47. Fumagalli F, Molteni R, Bedogni F, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. NeuroReport 2004;15:2109-2112.
48. Park SW, Lee CH, Cho HY, et al. Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal neuronal cultures. Synapse 2013;67:224-234.
49. Shao Z, Dyck LE, Wang H, Li XM. Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells. J Psychiatry Neurosci 2006;31:32-37.
50. Di Benedetto B, Kühn R, Nothdurfter C, et al. N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: A putative cellular mechanism for quetiapine as antidepressant. Neuropharmacology 2012;62:209-216.
51. Yuan XQ, Qiu G, Liu XJ, et al. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. NeuroImmunoModulation 2012;19:201-208.
52. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther 2008;14:153-164.
53. Bian Q, Kato T, Monji A, et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:42-48.
54. Kim H, Bang J, Chang HW, et al. Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol 2012;678:55-60.
55. Himmerich H, Schönherr J, Fulda S, et al. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 2011;45:1358-1365.
56. Igue R, Potvin S, Bah R, et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1695-1698.
57. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 1990;113:619-627.
58. Thöne J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: An overview of merits and culprits. Drug Healthc Patient Saf 2013;5:37-47.
59. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.
60. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.
61. Moharregh-Khiabani D, Blank A, Skripuletz T, et al. Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS ONE 2010;5:e11769.
62. Patten SB, Metz LM, Reimer MM. Biopsychosocial correlates of major depression in a multiple sclerosis population. Mult Scler 2000;6:115-120.
63. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorders and multiple sclerosis. Arch Neurol 1987;44:376-378.
64. Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: An epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542-545.
65. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: Population-based evidence of an association. Neurology 2005;65:1123-1235.
66. Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: Validating administrative data to support population-based surveillance. BMC Neurol 2013;13:16.
67. Honer WG, MacEwan GW, Gendron A, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012;73:13-20.
68. Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 2008;14:1127-1130.
69. Kaminska M, Kimoff RJ, Schwartzman K, Trojan DA. Sleep disorders and fatigue in multiple sclerosis: Evidence for association and interaction. J Neurol Sci 2011;302:7-13.
70. Datto C, Berggren L, Patel JB, Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: A randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31:492-502.
71. Juri C, Chaná P, Tapia J, Kunstmann C, Parrao T. Quetiapine for insomnia in Parkinson disease: Results from an open-label trial. J Clin Neuropharmacol 2005;28:185-187.
72. Pompili M, Rihmer Z, Gonda X, Serafini G, Sher L, Girardi P. Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: The role of quetiapine XR in the treatment of unipolar and bipolar depression. Riv Psichiatr 2012;47:489-497.
73. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-539.
74. Foley PL, Vesterinen HM, Laird BJ, et al. Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis. Pain 2013;154:632-642.
75. Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;12:CD008242.
76. Nagashima W, Kimura H, Ito M, et al. Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain. Clin Neuropharmacol 2012;35:273-277.
77. Seidel S, Aigner M, Ossege M. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage 2010;39:768-778.
78. Thase ME, Macfadden W, Weisler RH. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609.
79. Ondo WG, Tintner R, Voung KD. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.
80. Paleacu D, Barak Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: A 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008;23:393-400.
81. Borison RL, Arvanitis LA, Miller BG. ICI 204, 636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16:158-169.
82. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246.
83. Moteshafi H, Stip E. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: A meta-analysis. Expert Opin Drug Saf 2012;11:713-732.
84. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
85. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: A suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003;305:625-631.
86. Zhornitsky S, Potvin S, Stip E, Rompré PP. Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. Eur Neuropsychopharmacol 2010;20:695-703.
87. Fox RJ, Cronin T, Lin J, et al. Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol 2011;32:85-91.
88. Zhang Y, Zhu H, Mitchell JR, Costello F, Metz LM. T2 MRI texture analysis is a sensitive measure of tissue injury and recovery resulting from acute inflammatory lesions in multiple sclerosis. Neuroimage 2009;47:107-111.